Evidence map›Paper›PMID 41748291›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

Efficacy of CLDN18.2-Targeted Radiotheranostics in Patient-Derived Models of Gastric Cancer.

Paul C Klauser, Gina Dehlavi, Michele De Franco, Angelique Loor, Tara Viray, Alexa Michel, Besnik Qeriqi, Elisa de Stanchina, Lukas M Carter, Sebastian E Carrasco and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Materials today. Bio · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Paul C KlauserMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Gina DehlaviDepartment of Chemistry, Hunter College, City University of New York, New York, New York.
Michele De FrancoMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Angelique LoorMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Tara VirayMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Alexa MichelMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Besnik QeriqiAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
Elisa de StanchinaAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
Lukas M CarterDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
Sebastian E CarrascoLaboratory of Comparative Pathology, Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, and Rockefeller University, New York, New York.
Brian M ZeglisDepartment of Chemistry, Hunter College, City University of New York, New York, New York.
Yelena Y JanjigianGastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York; and.
Jason S LewisMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York; lewisj2@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Leveraging Pb-203/212 for the Theranostic Imaging and Therapy of Prostate CancerR35CA232130 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S. · 2019 to 2025
$8.2M
Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based TherapeuticsR01CA244327 · NCI · ROCKEFELLER UNIVERSITY · PI BOURNAZOS, STYLIANOS · 2020 to 2024
$3.0M
ANALYSIS OF TOBACCO DEPOSITIONS AND TRIAL TESTIMONYR01CA087486 · NCI · MICHIGAN PUBLIC HEALTH INSTITUTE · PI DAVIS, RONALD M · 2000 to 2003
$2.8M
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancerR01CA281801 · NCI · FRED HUTCHINSON CANCER CENTER · PI Delphine L Chen, PAUL D. LAMPE · 2023 to 2026
$2.4M
Novel Reagents for Rapid and Stable Thiol-Based BioconjugationsR01CA240963 · NCI · HUNTER COLLEGE · PI ZEGLIS, BRIAN MATTHEW · 2019 to 2023
$1.6M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA087486NCI NIH HHS R01 CA240963NCI NIH HHS R01 CA244327NCI NIH HHS R01 CA281801NCI NIH HHS R35 CA232130
6 · The paper itself

Abstract

Gastric cancer remains a major global health challenge with few durable treatments, and claudin-18.2 (CLDN18.2) has emerged as an attractive therapeutic target, highlighted by the modest activity of zolbetuximab in clinical trials. To further leverage CLDN18.2 as a therapeutic target, we developed a radiotheranostic strategy using [

Indexed as

ClaudinsStomach NeoplasmsAnimalsAntibodies, MonoclonalCell Line, TumorFemaleHumansMiceMolecular Targeted TherapyPositron-Emission TomographyRadioisotopesTreatment OutcomeZirconiumAntibodies, MonoclonalClaudinsCLDN18 protein, humanRadioisotopesZirconiumzolbetuximabclaudin18.2gastric cancerimmuno-PETradiotheranostics

Identifiers

PMID41748291
PMCPMC13138102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.